Latest News

Universal aspirin at the first prenatal visit lowers severe preeclampsia rates in high-risk pregnancies, delaying onset without raising hemorrhage or placental abruption risk.

ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Niels Lund, expert investigator, reveals how early type 2 diabetes care slashes greenhouse gas emissions, boosts life years, and curbs costly complications.

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Incretin-based therapies were associated with a lower risk of dementia compared with sulfonylureas in older adults with type 2 diabetes, highlighting potential cognitive benefits relevant to long-term diabetes management.

WADA tracks GLP-1s like Ozempic, Wegovy, and Zepbound at the Olympics as pharmacists weigh muscle-loss risks and sports pharmacy guidance.

Study links GLP-1 receptor agonists plus progestin to lower endometrial cancer risk, hinting at new prevention and treatment paths with fewer hysterectomies.

Both formulations were also well-tolerated and withdrawal was rare.

Patients need evidence that reflects real benefit.

The label change removes boxed warnings of cardiovascular disease, breast cancer, and probable dementia from certain hormone replacement therapy products.

Innovent’s trispecific antibody IBI3003 has received FDA fast track designation for R/R MM, supported by early clinical data showing strong efficacy and manageable safety in heavily pretreated and high-risk patients.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

Shifting federal vaccine guidance fuels parent confusion and uneven care, as clinicians lean on scientific consensus.

GDF15 can reshape prostate cancer prognosis and treatment; pharmacists track emerging biomarker panels and targeted therapies for metastatic disease.

The Break Up Big Medicine Act aims to address structural conflicts of interest.

H. pylori requires diagnosis, antibiotic- and acid-suppression-based therapy, and post-treatment eradication confirmation to prevent gastritis and cancer.

The FDA targets mass-marketed compounded GLP-1 drugs, warning of safety risks and deceptive ads as enforcement ramps up for weight-loss injectables.

The FDA declines to review Moderna’s mRNA flu vaccine filing over comparator choice, despite positive phase 3 results.

The updates allow for patients of reproductive age to complete pregnancy tests at home during or after treatment.

The phase 3 ADRIATIC trial demonstrates that consolidation durvalumab following concurrent chemoradiotherapy improves survival while maintaining health-related quality of life.

Vitamin B12 supports cognitive health, corrects deficiency in pills or shots, and helps pharmacists guide smart vitamin and supplement choices.